Form 8-K - Current report:
SEC Accession No. 0001683168-21-004865
Filing Date
2021-10-15
Accepted
2021-10-15 16:30:46
Documents
13
Period of Report
2021-10-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K xenetic_i8k.htm   iXBRL 8-K 31577
  Complete submission text file 0001683168-21-004865.txt   248635

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE xbio-20211012.xsd EX-101.SCH 3731
3 XBRL DEFINITION FILE xbio-20211012_def.xml EX-101.DEF 26583
4 XBRL LABEL FILE xbio-20211012_lab.xml EX-101.LAB 36561
5 XBRL PRESENTATION FILE xbio-20211012_pre.xml EX-101.PRE 25201
6 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_i8k_htm.xml XML 5316
Mailing Address 40 SPEEN STREET, SUITE 102 FRAMINGHAM MA 01701
Business Address 40 SPEEN STREET, SUITE 102 FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37937 | Film No.: 211326366
SIC: 2834 Pharmaceutical Preparations